CASI Pharmaceuticals, Inc. · OTC:CASIF

CASI Pharmaceuticals — Shareholder Meeting (June 2017)

35 slides from CASI Pharmaceuticals's shareholder meeting presentation, Jun 8, 2017

  1. Slide 1: Corporate Presentation: 2017 Annual Stockholders Meeting

    Corporate Presentation 2017 Annual Stockholders Meeting June 8, 2017

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statement

  3. Slide 3: Company Overview

    Company Overview  CASI is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market, with focus in China and the U.S.  CASI’s mission is to build an integrated biopha

  4. Slide 4: Investment Highlights

    Investment Highlights • Market: Well-positioned to pursue significant and unprecedented market opportunities in China and worldwide. • Model: Compelling business model with important North America/China synergies and competitive advantage with efficiency and effectiveness for drug development and co

  5. Slide 5: Financial Highlights

    Financial Highlights 12 Months Ended Three Months Ended March December 31, 31 2016 2015 2017 2016 Total revenues $ $ $ $ - 47,712 - - Research & 4,645,560 4,075,572 1,049,287 1,018,757 development General & 4,775,050 3,118,269 644,163 765,075 administrative Net loss (9,453,488) (7,206,423) (1,700,18

  6. Slide 6: Pipeline and Development Status

    Pipeline and Development Status Slide 6

  7. Slide 7: Milestone and Value Driver #1

    Milestone and Value Driver #1 Milestone and Value Driver #1 Reach inflection point for ENMD-2076 in Fibrolamellar Carcinoma, Ovarian Clear Cell Carcinoma and 2 other solid tumors – Complete a Phase 2 clinical trial for the treatment for Fibrolamellar Carcinoma – Reach inflection point for clinical t

  8. Slide 8: ENMD-2076 A NCE for Solid Tumors

    ENMD-2076 A NCE for Solid Tumors • Unique MOA: An orally active, small molecule, multi-targeted kinase inhibitor with selected inhibition of Aurora A, VEGFR, FGFR, and GF, and a Mechanism of Action against angiogenesis, proliferation and the cell cycle. • Strong Preclinical Data: demonstrated strong

  9. Slide 9: ENMD-2076 Antitumor Activity with Paclitaxel in Ovarian Model

    ENMD-2076 Antitumor Activity with Paclitaxel in a TOV-21G Ectopic Human Ovarian Carcinoma Model ENMD-2076 A NCE for Solid Tumors 100 Incidence Tumor Regression/Cohort (%) 90 • 9 mice/cohort 8/9 • 46 treatment days 80 • MTD regimen of Paclitaxel • Combination is tolerable 70 60 50 4/9 4/9 40 3/9 30 2

  10. Slide 10: ENMD-2076 Antitumor Activity in MDA-MB-231 TNBC Xenograft

    ENMD-2076 Antitumor Activity in MDA-MB-231 Human TNBC Tumor Xenograft Model Dose (mg/kg) Vehicl 2500 e 50 ( ) 200 ( ) 70% 2000 Response 51% TGI Regression Tumor Volume (mm3) Cmax (ng/mL) 1,483 3,870 1500 AUC (hng/mL) 8,208 32,805 50 mg/kg 1000 500 200 mg/kg 0 30 35 40 45 50 Rx Days Following Tumor

  11. Slide 11: ENMD-2076 Alone or in Combination with CDDP in TNBC Model

    ENMD-2076 Alone or in Combination with CDDP Against Orthotopic MDA-MB-231 Human TNBC Model Group Protocol-1 Protocol-2 Protocol-3 (Mice) Day 34- 49 Day 50- 64 Day 65-82 G1 No treatment ENMD-2076 Off study Protocol-1 Protocol-2 Protocol-3 200 mg/kg, po, qd 2000 6/8 regressions 1750 G2 ENMD-2076 No tr

  12. Slide 12: ENMD-2076 Significant Anti-Tumor Activities in Preclinical Studies

    ENMD-2076 Significant Anti-Tumor Activities in Preclinical Studies ENMD-2076 showed significant efficacy in suppressing FLC PDX model tumor growth in NOD-SCID mice at the 200 mg/kg dose evaluated in the study Slide 12

  13. Slide 13: ENMD-2076 Phase I Data

    Slide Partial (FLC) (STS) include: Phase ‒ 160 mg/m2/d Cancer (TNBC) ‒ Ovarian clear cell carcinoma (OCCC) Recommended dose: Data supports further ‒ Soft Tissue Sarcoma 13 II clinical trials ‒ Triple-Negative Breast Survival 6 months patients ‒ Fibrolamellar Carcinoma Response/Progression Free -50%

  14. Slide 14: ENMD-2076 Phase II Data Ovarian Cancer

    ENMD-2076 Phase II Data Ovarian Cancer ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer RECIST Response Effect on CA125 • Overall response rate ‒ PR: 8% ‒ PR/SD: 58% ‒ PFS 6: 22% • Stronger activities observed in clear

  15. Slide 15: Phase 2 Trials Ongoing - Identifying Correlative Biomarkers

    Phase 2 Trials Ongoing - Focusing on Identifying Correlative Biomarkers ENMD-2076 Phase II Phase II Study of Oral Phase II Study of ENMD- Phase II Study of Oral Phase II Study of Oral ENMD-2076 Administrated 2076 in Patients with ENMD-2076 Administrated ENMD-2076 to Previously Treated Locally to Pat

  16. Slide 16: Phase II Trial Ovarian Clear Cell Carcinoma

    Phase II Trial Ovarian Clear Cell Carcinoma A Single Arm, Single Agent, Phase II Trials of ENMD-2076 in Advanced OCCC Patients (Completed) Advanced ovarian clear cell cancer patients with 1-3 lines of previous regiment and relapsed/resistant to platinum (N=40) Single arm, single agent ENMD-2076 trea

  17. Slide 17: Phase II OCCC Trial ARID1A

    Phase II OCCC Trial ARID1A ARID1A positive IHC Archival ARID1A Samples Total analyzed 32 Positive 14 (44%) Negative 18 (56%) Heterogenous 0 ARID1A negative Slide 17

  18. Slide 18: ENMD-2076 Phase 2 OCCC PFS Data

    ENMD-2076 Phase 2 OCCC PFS Data Slide 18 Confidential

  19. Slide 19: ENMD-2076 Phase 2 OCCC

    ENMD-2076 Phase 2 OCCC Best Target Lesions change from baseline (%) Slide 19 Confidential

  20. Slide 20: ENMD-2076 Phase 2 OCCC

    ENMD-2076 Phase 2 OCCC ARID1A-IHC and PFS correlation Negative (N=19) Positive (N=17) P=0.023 Slide 20 Confidential

  21. Slide 21: ENMD-2076 For Treatment of FLC

    ENMD-2076 For Treatment of FLC FLC, fibrolamellar carcinoma, a rare type of hepatocellular carcinoma (HCC) liver cancer: – Accounts for 0.6- 8.6% of HCC. The total incidence of HCC is estimated to be 780,000 each year worldwide based on the World Health Organization. – Primarily affects adolescents

  22. Slide 22: ENMD-2076 Significant Anti-tumor Activities in Preclinical Studies

    ENMD-2076 Significant Anti-tumor Activities in Preclinical Studies ENMD-2076 showed significant efficacy in suppressing FLC PDX model tumor growth in NOD-SCID mice at the 200 mg/kg dose evaluated in the study Slide 22

  23. Slide 23: Aurora A PK A potential target for FLC targeted therapy

    Aurora A PK A potential target for FLC targeted therapy Slide 23

  24. Slide 24: Phase 2 Trial in FLC - Ongoing

    Phase 2 Trial in FLC - Ongoing A single arm, single agent, 2 stage design multi-center Phase 2 trial of ENMD-2076 for the treatment of advanced FLC patients Stage 1: Recruit 16 advanced FLC patients with >1 line of treatment (N=16) Interim futility analysis after 16 patients have reached endpoint of

  25. Slide 25: ENMD-2076 Potential First Therapy to Treat Fibrolamellar Carcinoma

    ENMD-2076 Potential First Therapy to Treat Fibrolamellar Carcinoma • Orphan Drug Designation in HCC/FLC in the US and EU • Clear clinical and regulatory development pathway – Recent FDA Meeting Minutes provide clear guidance on the clinical and regulatory path to lead to marketing approval: • A sing

  26. Slide 26: Milestone and Value Driver #2

    Milestone and Value Driver #2 Milestone and Value Driver #2 • Complete Import Drug Registration and Launch in China • In-license Additional Drug Candidates for Global and/or China rights Slide 26

  27. Slide 27: Pipeline In-licensed for Greater China Market

    Pipeline In-licensed for Greater China Market Products Under Development for Import Drug Registration in Greater China Region Partner’s Product Description Indication Status Status Approved and Advanced adult Import Drug vincristine Marketed ex- MARQIBO sulfate LIPOSOME Ph-acute Registration China ®

  28. Slide 28: ZEVALIN, MARQIBO, EVOMELA

    ZEVALIN®, MARQIBO®, EVOMELA™ • Significant competitive advantage in greater China’s marketplace due to its strong IP position and significant technology barriers. • Minimal clinical and regulatory risks, although it may take time to get marketing approval, particularly in China. • The value of each

  29. Slide 29: The Market Potential in China

    The Market Potential in China • Annual incidence of NHL is estimated at 46,563 new cases with a mortality of 29,201 cases in China in 2015*; the five-year prevalence is estimated at 69,200 cases*, including 13% of cases (or 8,996) in FNHL and 30% of cases (or 20,760) in DLBCL. • In China, hospitals

  30. Slide 30: The Market Potential in China

    The Market Potential in China • Annual incidence of leukemia is estimated at 70,240 cases with a mortality of 58,746 cases in China in 2015* • The five-year prevalence is estimated at 73,694 cases* including about 10,000 Ph- adult ALL • The retail cost of MARQIBO in the U.S. per dose is approximatel

  31. Slide 31: The Market Potential in China

    The Market Potential in China • Annual incidence of multiple myeloma is estimated at 12,197 cases with a mortality of 9,038 cases in China in 2015* • The five-year prevalence is estimated at 14,100 cases* • The retail cost for branded Alkeran injection in the U.S. per dose is approximately $1,971/50

  32. Slide 32: Milestone and Value Driver #3

    Milestone and Value Driver #3 Milestone and Value Driver #3 Expanding our product pipeline Strategy: In-license approved or late-stage clinical drug candidates for the greater China market Strategy: In-license/Internally develop early stage new innovative drug candidates focusing on proof of concept

  33. Slide 33: Strategic Imperatives

    Strategic Imperatives 1. Capitalize on strength and expertise in U.S./China global drug development 2. Continue to expand drug pipeline 3. Advance late-stage products to commercial launch 4. Leverage resources, funding, and other opportunities in China 5. Sustain momentum and long-term growth Slide

  34. Slide 34: Thank you

    Thank you Slide 34

  35. Slide 35: NASDAQ: CASI www.casipharmaceuticals.com

    NASDAQ: CASI www.casipharmaceuticals.com Slide 35

CASI Pharmaceuticals — Shareholder Meeting (June 2017) on 6ix